You are here

Treatment Phase Completed for Cubicin Endocarditis/Bacteremia Study

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 22, 2005--Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced all of the enrolled patients have completed the treatment phase of the trial and the remaining patients are now in the follow-up period in this study. Data from 191 patients were reviewed at the Independent Data Monitoring Committee (DMC) Meeting, completing the fifth planned safety review of patients enrolled in Cubist's ongoing international Phase 3 clinical trial examining the safety and efficacy of Cubicin(R) (daptomycin for injection) in the treatment of infective endocarditis and complicated bacteremia caused by Staphylococcus aureus. As all patients have now completed treatment, no decision regarding the continuation of the study was required from the DMC.

Due to the high mortality rate associated with endocarditis, blinded clinical data from patients enrolled in the study are provided to the DMC at pre-determined intervals to identify any safety-related issues. Patients with blood cultures positive for the presence of S. aureus were enrolled at sites in the U.S. and certain Western European countries. The study protocol includes patients with infective endocarditis and complicated or uncomplicated bacteremia. In the study, patients received either CUBICIN, at 6 mg/kg once daily, or the current standards of care, vancomycin in patients with confirmed methicillin-resistant S. aureus (MRSA) infection or a semi-synthetic penicillin if susceptible S. aureus is confirmed. Cubist continues to expect to report results from this trial in mid 2005.

About Cubicin
CUBICIN is currently the only once-daily bactericidal antibiotic approved in the U.S. indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pyogenes, S. agalactiae, S. dysgalactiae subsp equisimilis and Enterococcus faecalis (vancomycin-susceptible strains only). CUBICIN is not indicated for the treatment of pneumonia. Most adverse events reported in clinical trials were mild or moderate in intensity and the most common were constipation, nausea, injection site reactions, and headache. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN, CUBICIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria susceptible to CUBICIN. For full prescribing information, visit www.Cubicin.com.

Source: Cubist Pharmaceuticals

Recent Headlines

Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Will Have a Longer Shelf Life Than Current, Expired Stockpile
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Record-High Number of Cases in France, Italy, Greece, Other Locations